Have a feature idea you'd love to see implemented?
Let us know!
TCRX TScan Therapeutics Inc
Price (delayed)
$4.97
Market cap
$263.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$107.16M
Highlights
The equity has soared by 108% from the previous quarter and by 34% YoY
The EPS has soared by 67% YoY and by 19% QoQ
The company's net income fell by 28% YoY and by 8% QoQ
TCRX's gross profit is down by 26% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of TCRX
Market
Valuations
Earnings
Shares outstanding
52.97M
Market cap
$263.28M
Enterprise value
$107.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.03
Price to sales (P/S)
46.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.78
Revenue
$12.2M
EBIT
-$100.67M
EBITDA
-$95.73M
Free cash flow
-$74.7M
Per share
Balance sheet
Liquidity
EPS
-$0.95
Free cash flow per share
-$0.66
Book value per share
$4.83
Revenue per share
$0.11
TBVPS
$3.31
Total assets
$374.87M
Total liabilities
$119.65M
Debt
$91.07M
Equity
$255.22M
Working capital
$260.96M
Debt to equity
0.36
Current ratio
7.77
Quick ratio
7.85
Net debt/EBITDA
1.63
Margins
Efficiency
Dividend
EBITDA margin
-784.7%
Gross margin
100%
Net margin
-855.8%
Operating margin
-914.7%
Return on assets
-35.4%
Return on equity
-59.8%
Return on invested capital
-56.2%
Return on capital employed
-29.9%
Return on sales
-825.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TCRX stock price
How has the TScan Therapeutics stock price performed over time
Intraday
-2.36%
1 week
-5.51%
1 month
-2.55%
1 year
52.92%
YTD
-14.75%
QTD
-0.2%
Financial performance
How have TScan Therapeutics's revenue and profit performed over time
Revenue
$12.2M
Gross profit
$12.2M
Operating income
-$111.59M
Net income
-$104.41M
Gross margin
100%
Net margin
-855.8%
The operating margin has plunged by 82% YoY and by 33% from the previous quarter
TScan Therapeutics's net margin has shrunk by 72% YoY and by 31% QoQ
The company's operating income fell by 35% YoY and by 9% QoQ
The company's net income fell by 28% YoY and by 8% QoQ
Growth
What is TScan Therapeutics's growth rate over time
Valuation
What is TScan Therapeutics stock price valuation
P/E
N/A
P/B
1.03
P/S
46.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.78
The EPS has soared by 67% YoY and by 19% QoQ
The equity has soared by 108% from the previous quarter and by 34% YoY
The price to book (P/B) is 39% lower than the last 4 quarters average of 1.7
The price to sales (P/S) is 34% higher than the last 4 quarters average of 34.4
TScan Therapeutics's revenue has decreased by 26% YoY and by 18% QoQ
Efficiency
How efficient is TScan Therapeutics business performance
The ROS has shrunk by 73% YoY and by 31% QoQ
TScan Therapeutics's ROIC has increased by 14% YoY but it has decreased by 4.7% from the previous quarter
TScan Therapeutics's ROE has increased by 11% YoY and by 2.1% from the previous quarter
The company's return on assets rose by 7% YoY but it fell by 2.6% QoQ
Dividends
What is TCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TCRX.
Financial health
How did TScan Therapeutics financials performed over time
The total assets has soared by 56% since the previous quarter and by 18% year-on-year
TCRX's current ratio is up by 49% since the previous quarter and by 13% year-on-year
TScan Therapeutics's debt is 64% lower than its equity
The equity has soared by 108% from the previous quarter and by 34% YoY
The debt to equity has dropped by 52% since the previous quarter and by 22% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.